X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1370) 1370
Book Review (227) 227
Conference Proceeding (96) 96
Publication (58) 58
Magazine Article (32) 32
Newsletter (20) 20
Newspaper Article (5) 5
Book Chapter (4) 4
Dissertation (2) 2
Trade Publication Article (2) 2
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (904) 904
humans (870) 870
piperazines - therapeutic use (595) 595
male (454) 454
piperazine (357) 357
female (309) 309
piperazines - economics (283) 283
adult (231) 231
middle aged (228) 228
imatinib mesylate (226) 226
sildenafil citrate (224) 224
pharmacology & pharmacy (204) 204
piperazines - adverse effects (189) 189
pyrimidines - therapeutic use (186) 186
piperazines - pharmacology (183) 183
treatment outcome (180) 180
piperazines - administration & dosage (173) 173
aged (166) 166
antineoplastic agents - therapeutic use (161) 161
piperazin (161) 161
benzamides (159) 159
animals (158) 158
purines (140) 140
sulfones (136) 136
analysis (125) 125
erectile dysfunction - drug therapy (125) 125
cost-benefit analysis (116) 116
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (112) 112
drug therapy (110) 110
oncology (104) 104
co2-entfernung (99) 99
amines (97) 97
double-blind (97) 97
united states (96) 96
carbon-dioxide-removal (95) 95
antipsychotic agents - therapeutic use (93) 93
medicine, general & internal (93) 93
lösungsmittel (92) 92
piperazines - chemistry (92) 92
psychiatry (89) 89
abridged index medicus (88) 88
care and treatment (88) 88
antineoplastic agents - economics (85) 85
drug costs (84) 84
engineering, chemical (84) 84
research (84) 84
absorption (82) 82
pyrimidines - economics (82) 82
adolescent (81) 81
capture (80) 80
solvents (78) 78
co2 capture (77) 77
monoethanolamine (77) 77
sildenafil (75) 75
energy (74) 74
imatinib (74) 74
schizophrenia (72) 72
dose-response relationship, drug (71) 71
schizophrenia - drug therapy (71) 71
aripiprazole (69) 69
energy & fuels (69) 69
medicine & public health (69) 69
amin (68) 68
prasugrel hydrochloride (68) 68
phosphodiesterase inhibitors - therapeutic use (67) 67
carbon dioxide (66) 66
clinical trials as topic (66) 66
efficacy (66) 66
thiazoles - therapeutic use (66) 66
time factors (65) 65
young adult (64) 64
double-blind method (63) 63
carbon-dioxide (62) 62
erectile dysfunction (62) 62
hematology (62) 62
kinetics (62) 62
engineering, environmental (61) 61
chronic myelogenous leukemia (59) 59
chronic myeloid leukemia (59) 59
cancer (58) 58
protein kinase inhibitors - therapeutic use (57) 57
rats (57) 57
aqueous-solutions (56) 56
neurosciences (56) 56
piperazines (55) 55
quality of life (55) 55
thiophenes - therapeutic use (55) 55
ticlopidine - analogs & derivatives (55) 55
absorption-of-carbon-dioxide (54) 54
aged, 80 and over (54) 54
therapy (54) 54
quinolones - therapeutic use (53) 53
solubility (53) 53
administration, oral (52) 52
health aspects (50) 50
impotence (50) 50
monoethanolamin (50) 50
retrospective studies (50) 50
purines - therapeutic use (49) 49
randomized controlled trials as topic (49) 49
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1405) 1405
Swedish (9) 9
German (8) 8
French (6) 6
Dutch (2) 2
Japanese (2) 2
Portuguese (2) 2
Hungarian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


American Journal of Managed Care, ISSN 1088-0224, 2014, Volume 20, Issue 3, pp. e90 - e97
Objectives: A "chiral switch" occurs in the pharmaceutical market when a drug made up of 2 enantiomer forms is replaced with a purified single-enantiomer... 
MEDICATION | NAMES | MULTICENTER | EROSIVE ESOPHAGITIS | OMEPRAZOLE | RANDOMIZED CONTROLLED-TRIAL | 8-WEEK COMPARATIVE TRIAL | MEDICINE, GENERAL & INTERNAL | COST | HEALTH CARE SCIENCES & SERVICES | DOUBLE-BLIND | HEALTH POLICY & SERVICES | HEALTH | Proton Pump Inhibitors - economics | Formoterol Fumarate | Hypnotics and Sedatives - chemistry | Medicaid - economics | Stereoisomerism | United States | Humans | Dexmethylphenidate Hydrochloride - chemistry | Drugs, Generic - economics | Piperazines - economics | Esomeprazole - chemistry | Drug Approval | Piperazines - chemistry | Esomeprazole - economics | Eszopiclone | Azabicyclo Compounds - chemistry | Benzhydryl Compounds - chemistry | Antidotes - economics | Bronchodilator Agents - chemistry | Levoleucovorin - chemistry | Histamine H1 Antagonists, Non-Sedating - economics | Dexmethylphenidate Hydrochloride - economics | Dexlansoprazole - chemistry | Retrospective Studies | Central Nervous System Stimulants - economics | United States Food and Drug Administration | Wakefulness-Promoting Agents - chemistry | Levoleucovorin - economics | Antidotes - chemistry | Bronchodilator Agents - economics | Azabicyclo Compounds - economics | Benzhydryl Compounds - economics | Cetirizine - chemistry | Cetirizine - economics | Ethanolamines - economics | Ethanolamines - chemistry | Patents as Topic | Hypnotics and Sedatives - economics | Wakefulness-Promoting Agents - economics | Drug Prescriptions - statistics & numerical data | Proton Pump Inhibitors - chemistry | Central Nervous System Stimulants - chemistry | Dexlansoprazole - economics | Histamine H1 Antagonists, Non-Sedating - chemistry | Clinical trials | Prescription drugs | Trends | Comparative analysis | Health administration
Journal Article
Journal of Thrombosis and Haemostasis, ISSN 1538-7933, 01/2013, Volume 11, Issue 1, pp. 81 - 91
Background:  The CYP2C19 genotype is a predictor of adverse cardiovascular events in acute coronary syndrome (ACS) patients undergoing percutaneous coronary... 
clopidogrel | cost‐effectiveness | prasugrel | antiplatelet therapy | genetic testing | acute coronary syndromes | Antiplatelet therapy | Prasugrel | Clopidogrel | Genetic testing | Acute coronary syndromes | Cost-effectiveness | cost-effectiveness | LAST YEAR | CYP2C19 GENOTYPE | TREATED PATIENTS | BYPASS GRAFT-SURGERY | ATRIAL-FIBRILLATION | ACUTE MYOCARDIAL-INFARCTION | PERIPHERAL VASCULAR DISEASE | ST-SEGMENT ELEVATION | HEMATOLOGY | OF-CARE | CLINICAL-OUTCOMES | Prasugrel Hydrochloride | Predictive Value of Tests | Thiophenes - therapeutic use | Percutaneous Coronary Intervention - mortality | Acute Coronary Syndrome - economics | Humans | Aryl Hydrocarbon Hydroxylases - genetics | Thiophenes - metabolism | Medicare - economics | Models, Economic | Pharmacogenetics - economics | Time Factors | Ticlopidine - economics | Myocardial Infarction - etiology | Insurance, Health, Reimbursement - economics | Quality-Adjusted Life Years | Genetic Predisposition to Disease | Risk Assessment | Gene Frequency | Risk Factors | Piperazines - therapeutic use | Ticlopidine - analogs & derivatives | Phenotype | Acute Coronary Syndrome - therapy | Thrombosis - genetics | Percutaneous Coronary Intervention - economics | Percutaneous Coronary Intervention - adverse effects | Thrombosis - economics | Drug Costs | Platelet Aggregation Inhibitors - economics | Markov Chains | Ticlopidine - therapeutic use | United States | Acute Coronary Syndrome - mortality | Piperazines - economics | Piperazines - metabolism | Computer Simulation | Hemorrhage - etiology | Ticlopidine - metabolism | Thiophenes - economics | Platelet Aggregation Inhibitors - metabolism | Thrombosis - prevention & control | Platelet Aggregation Inhibitors - therapeutic use | Decision Support Techniques | Kaplan-Meier Estimate | Treatment Outcome | Cerebrovascular Disorders - etiology | Aryl Hydrocarbon Hydroxylases - metabolism | Disease-Free Survival | Health Care Costs | Cytochrome P-450 CYP2C19 | Cost-Benefit Analysis | Acute Coronary Syndrome - diagnosis | Acute Coronary Syndrome - genetics | Genetic Testing - economics | Transluminal angioplasty | Care and treatment | Medicare | Analysis | Cardiac patients | Cytochrome P-450 | Markov processes | Cost benefit analysis | Coronary heart disease | Genetic screening | Angina pectoris | Genotype & phenotype | Index Medicus
Journal Article
European Journal of Cancer, ISSN 0959-8049, 11/2017, Volume 85, pp. 146 - 154
The addition of to improves progression-free survival in the first-line treatment of hormone receptor positive advanced breast cancer (ABC). This study... 
Advanced breast cancer | Cost-effectiveness | Letrozole | Cost-utility | Palbociclib | SURVIVAL | 1ST-LINE TREATMENT | CANADA | CARE | SOCIETY | OF-LIFE | WOMEN | THERAPY | ONCOLOGY | AROMATASE INHIBITORS | Drug Costs | Nitriles - economics | Breast Neoplasms - economics | Humans | Piperazines - economics | Antineoplastic Agents - therapeutic use | Models, Economic | Protein Kinase Inhibitors - adverse effects | Breast Neoplasms - chemistry | Pyridines - adverse effects | Stochastic Processes | Time Factors | Antineoplastic Agents - adverse effects | Computer Simulation | Antineoplastic Combined Chemotherapy Protocols - economics | Triazoles - economics | Female | Aromatase Inhibitors - therapeutic use | Pyridines - therapeutic use | Triazoles - therapeutic use | Protein Kinase Inhibitors - economics | Biomarkers, Tumor - analysis | Decision Support Techniques | Treatment Outcome | Piperazines - therapeutic use | Breast Neoplasms - drug therapy | Piperazines - adverse effects | Antineoplastic Agents - economics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aromatase Inhibitors - economics | Breast Neoplasms - pathology | Protein Kinase Inhibitors - therapeutic use | Cost-Benefit Analysis | Pyridines - economics | Quality of Life | Decision Trees | Ontario | Nitriles - therapeutic use | Analysis | Breast cancer | Hormones | Health care | Sensitivity analysis | Statistical analysis | Computer simulation | Clinical trials | Probabilistic methods | Parameter sensitivity | Probability distribution functions | Parameter uncertainty | Discrete event systems | Cost analysis | Cancer | Index Medicus
Journal Article
Gynecologic Oncology, ISSN 0090-8258, 2015, Volume 139, Issue 1, pp. 59 - 62
Abstract Purpose To determine the cost-effectiveness of olaparib, a PARP inhibitor, as maintenance therapy for platinum-sensitive (PS) recurrent ovarian... 
Hematology, Oncology and Palliative Medicine | Obstetrics and Gynecology | BRCA | PARP inhibitiors | Olaparib | Cost-effectiveness | Ovarian cancer | GYNECOLOGIC-ONCOLOGY-GROUP | STAGE-III | CHEMOTHERAPY | PACLITAXEL | OBSTETRICS & GYNECOLOGY | TRIAL | WOMEN | CISPLATIN | ONCOLOGY | Neoplasm Recurrence, Local - economics | United States | Humans | Neoplasm Recurrence, Local - drug therapy | Piperazines - economics | Phthalazines - economics | Antineoplastic Agents - therapeutic use | Models, Economic | Ovarian Neoplasms - genetics | Maintenance Chemotherapy - methods | Antineoplastic Combined Chemotherapy Protocols - economics | Genes, BRCA2 | Germ-Line Mutation | Female | Genes, BRCA1 | Paclitaxel - administration & dosage | Ovarian Neoplasms - drug therapy | Paclitaxel - economics | Decision Support Techniques | Carboplatin - administration & dosage | Piperazines - therapeutic use | Carboplatin - economics | Antineoplastic Agents - economics | Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use | Disease-Free Survival | Poly(ADP-ribose) Polymerase Inhibitors - economics | Phthalazines - therapeutic use | Ovarian Neoplasms - economics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cost-Benefit Analysis | Maintenance Chemotherapy - economics | Neoplasm Recurrence, Local - genetics | Relapse | Cost benefit analysis | Analysis | Diseases | Index Medicus
Journal Article
Circulation, ISSN 0009-7322, 01/2010, Volume 121, Issue 1, pp. 71 - 79
Background-In patients with acute coronary syndromes and planned percutaneous coronary intervention, the Trial to Assess Improvement in Therapeutic Outcomes by... 
Infarction | Coronary disease | Thrombus | Cost- benefit analysis | Revascularization | revascularization | CARDIAC & CARDIOVASCULAR SYSTEMS | CONFIDENCE-INTERVALS | CARDIOVASCULAR EVENTS | infarction | thrombus | coronary disease | IMPACT | cost-benefit analysis | PERIPHERAL VASCULAR DISEASE | ST-SEGMENT ELEVATION | HEMATOLOGY | CLINICAL-OUTCOMES | Platelet Aggregation Inhibitors - economics | Prasugrel Hydrochloride | Thiophenes - therapeutic use | United States - epidemiology | Myocardial Infarction - mortality | Follow-Up Studies | Ticlopidine - therapeutic use | Acute Coronary Syndrome - economics | Humans | Acute Coronary Syndrome - mortality | Hemorrhage - mortality | Piperazines - economics | Angioplasty, Balloon, Coronary | Drug Costs - statistics & numerical data | Life Expectancy | Ticlopidine - economics | Myocardial Infarction - economics | Thiophenes - economics | Stroke - mortality | Platelet Aggregation Inhibitors - therapeutic use | Databases, Factual | Multicenter Studies as Topic - statistics & numerical data | Randomized Controlled Trials as Topic - statistics & numerical data | Thrombolytic Therapy - economics | Combined Modality Therapy | Piperazines - therapeutic use | Ticlopidine - analogs & derivatives | Acute Coronary Syndrome - drug therapy | Outcome and Process Assessment (Health Care) - economics | Myocardial Infarction - drug therapy | Cost-Benefit Analysis | Hospitalization - economics | Usage | Patient outcomes | Clopidogrel | Drug therapy | Comparative analysis | Health aspects | Heart attack | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Journal Article
Clinical Therapeutics, ISSN 0149-2918, 2012, Volume 34, Issue 8, pp. 1774 - 1787
Abstract Background Chronic graft-versus-host disease (cGvHD) is the leading cause of late nonrelapse mortality (transplant-related mortality) after... 
Internal Medicine | Medical Education | cost-effectiveness | extracorporeal photopheresis | chronic graft | host disease | Host disease | Extracorporeal photopheresis | Cost-effectiveness | Chronic graft | EXTRACORPOREAL PHOTOCHEMOTHERAPY | T-CELL LYMPHOMA | MONOCLONAL-ANTIBODY | TRANSPLANTATION | ECONOMIC-EVALUATION | RITUXIMAB | SALVAGE THERAPY | PHARMACOLOGY & PHARMACY | PHOTOPHERESIS | REFRACTORY CHRONIC GVHD | IMATINIB MESYLATE | Drug Costs | Graft vs Host Disease - therapy | Humans | Immunosuppressive Agents - therapeutic use | Needs Assessment - economics | Photopheresis - economics | Piperazines - economics | Health Services Needs and Demand - economics | Models, Economic | Time Factors | Computer Simulation | Immunosuppressive Agents - economics | Graft vs Host Disease - diagnosis | Graft vs Host Disease - economics | Quality-Adjusted Life Years | Photopheresis - adverse effects | Antibodies, Monoclonal, Murine-Derived - economics | National Health Programs - economics | Rituximab | Treatment Outcome | Piperazines - therapeutic use | Pyrimidines - economics | Imatinib Mesylate | Piperazines - adverse effects | Spain | Health Care Costs | Pyrimidines - therapeutic use | Cost-Benefit Analysis | Pyrimidines - adverse effects | Immunosuppressive Agents - adverse effects | Benzamides | Antibodies, Monoclonal, Murine-Derived - adverse effects | Chronic Disease | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Health Care Rationing - economics | Transplantation | Hematopoietic stem cells | Stem cells | Studies | Transplants & implants | Mortality | Index Medicus | Economia de la salut | Espanya | Medical economics
Journal Article
Journal Article
American Journal of Cardiology, The, ISSN 0002-9149, 2013, Volume 112, Issue 3, pp. 355 - 362
Assays monitoring P2Y12 platelet reactivity can accurately predict which patients will have a poor response to clopidogrel. We sought to determine the... 
Cardiovascular | INFARCTION | CARDIAC & CARDIOVASCULAR SYSTEMS | CLOPIDOGREL | TICAGRELOR | ASPIRIN AND/OR RESISTANCE | CARDIOVASCULAR-DISEASE | PATIENTS SHOWING RESISTANCE | TAILORING TREATMENT | INTERVENTION | PRIMARY PREVENTION | TIROFIBAN | Platelet Aggregation Inhibitors - economics | Prasugrel Hydrochloride | Thiophenes - therapeutic use | Markov Chains | Ticlopidine - therapeutic use | Acute Coronary Syndrome - economics | Humans | Receptors, Purinergic P2Y12 - drug effects | Acute Coronary Syndrome - mortality | Drugs, Generic - economics | Piperazines - economics | Male | Drugs, Generic - therapeutic use | Dose-Response Relationship, Drug | Drug Costs - statistics & numerical data | Receptors, Purinergic P2Y12 - blood | Adenosine - therapeutic use | Ticlopidine - economics | Female | Myocardial Revascularization - economics | Thiophenes - economics | Platelet Aggregation Inhibitors - therapeutic use | Quality-Adjusted Life Years | Survival Rate | Piperazines - therapeutic use | Drug Therapy, Combination - economics | Ticlopidine - analogs & derivatives | Platelet Function Tests - economics | Acute Coronary Syndrome - drug therapy | Adenosine - analogs & derivatives | Cost-Benefit Analysis | Adenosine - economics | Aged | Decision Trees | Cohort Studies | Markov processes | Monte Carlo method | Coronary heart disease | Analysis | Cardiac patients | Medical care, Cost of | Aspirin | Heart attacks | Drug therapy | Acute coronary syndromes | Index Medicus | Abridged Index Medicus
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 7/2016, Volume 158, Issue 1, pp. 51 - 57
Journal Article
Journal Article
Journal Article